Aegis Capital Supports ‘Buy’ Rating, Higher Stock Price Target for Progenics (PGNX) Following Strong Q3 Results
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), a company focused on the development of innovative treatments and therapies for cancer, in particular prostate cancer, recently released its financial results for the third quarter of 2016, reporting higher revenue and net income compared to the third quarter of 2015. The growth can be primarily attributed to the FDA approval and U.S. commercial launch of its flagship product, oral Relistor®, for the treatment of opioid induced constipation in patients suffering from chronic non-cancer pain, according to an Aegis Capital Corp. analysis (http://nnw.fm/K8l26) released on November 8, one day after the Q3 results. The Aegis…







